{"schema_version":"1","generated_at":"2026-10-28T18:58:41.213Z","data_as_of":null,"url":"https://www.findmykol.com/kol/namrata-chandhok","json_url":"https://www.findmykol.com/kol/namrata-chandhok/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"namrata-chandhok","name":"Namrata Chandhok","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Miami","state":"FL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1811336696","orcid":"0000-0002-7464-4509","openalex":"A5058367777"},"summary":"Namrata Chandhok is an Oncology physician. OpenAlex indexes 79 publications with 1,185 citations (h-index 11).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":79,"cited_by_count":1185,"h_index":11,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":16,"program_years":{"first":2021,"last":null},"rows_total":20,"shown":3,"withheld":17,"rows":[{"payer":"Takeda Pharmaceuticals U.S.A., Inc.","program_year":2025,"amount_usd":3738.49,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1811336696"},{"payer":"Geron Corporation","program_year":2025,"amount_usd":2727.86,"payment_count":5,"source_url":"https://openpaymentsdata.cms.gov/search?query=1811336696"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":1925,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1811336696"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1811336696","source":"payments"},"prescribing":{"data_year":2024,"areas_total":5,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":45.7,"classes_total":4,"classes":[{"class":"Nucleoside Metabolic Inhibitor","setting":"prescribed","share_pct":16.3,"drugs":[{"name":"Inqovi","share_pct":70.2},{"name":"Onureg","share_pct":29.8}],"max_beneficiaries":null},{"class":"BCL-2 Inhibitor","setting":"prescribed","share_pct":15.2,"drugs":[{"name":"Venclexta","share_pct":100}],"max_beneficiaries":12}]},{"area":"Anti-infectives","share_pct":24.2,"classes_total":3,"classes":[{"class":"Fluoroquinolone Antibacterial","setting":"prescribed","share_pct":15.6,"drugs":[{"name":"Levofloxacin","share_pct":100}],"max_beneficiaries":11},{"class":"Triazole and tetrazole derivatives","setting":"prescribed","share_pct":4.8,"drugs":[{"name":"Cresemba","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":13.1,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":13.1,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":12}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy","year":2026,"journal":"Haematologica","source_url":"https://doi.org/10.3324/haematol.2025.300374","status":"verified"},{"title":"Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database","year":2026,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-026-01543-6","status":"verified"},{"title":"Measurable residual disease in hematologic malignancies: a biomarker in search of a standard","year":2025,"journal":"EClinicalMedicine","source_url":"https://doi.org/10.1016/j.eclinm.2025.103348","status":"verified"},{"title":"Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-768","status":"verified"},{"title":"Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-635","status":"verified"}],"source":"works"},"contact":{"address_1":"1475 NW 12TH AVE","city":"Miami","state":"FL","zip":"331361002","phone":"305-243-5302","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1811336696","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":17,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2019-09-11","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}